Total Payments
$1.0M
2024 Payments
$219,025
Companies
43
Transactions
719
Medicare Patients
375
Medicare Billing
$44,132
Payment Breakdown by Category
Consulting$673,814 (64.3%)
Other$168,872 (16.1%)
Research$117,399 (11.2%)
Travel$70,469 (6.7%)
Food & Beverage$10,134 (1.0%)
Education$7,114 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $673,814 | 267 | 64.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $140,517 | 92 | 13.4% |
| Unspecified | $117,399 | 97 | 11.2% |
| Travel and Lodging | $70,469 | 124 | 6.7% |
| Honoraria | $28,355 | 7 | 2.7% |
| Food and Beverage | $10,134 | 131 | 1.0% |
| Education | $7,114 | 1 | 0.7% |
Payments by Type
General
$930,403
622 transactions
Research
$117,399
97 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $311,138 | 189 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $110,190 | 64 | $0 (2024) |
| Eli Lilly and Company | $92,190 | 95 | $0 (2024) |
| Janssen Research & Development, LLC | $84,280 | 55 | $0 (2024) |
| Merck Sharp & Dohme LLC | $46,275 | 32 | $0 (2024) |
| Gilead Sciences, Inc. | $34,714 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $32,443 | 16 | $0 (2024) |
| ABBVIE INC. | $31,917 | 38 | $0 (2024) |
| Janssen Biotech, Inc. | $27,230 | 24 | $0 (2024) |
| Genentech, Inc. | $23,815 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $219,025 | 122 | Eli Lilly and Company ($44,336) |
| 2023 | $149,786 | 106 | PFIZER INC. ($51,995) |
| 2022 | $85,985 | 63 | Janssen Research & Development, LLC ($29,043) |
| 2021 | $104,227 | 65 | PFIZER INC. ($25,570) |
| 2020 | $105,844 | 50 | PFIZER INC. ($34,040) |
| 2019 | $119,367 | 92 | PFIZER INC. ($40,735) |
| 2018 | $144,306 | 106 | PFIZER INC. ($66,498) |
| 2017 | $119,260 | 115 | PFIZER INC. ($36,419) |
All Payment Transactions
719 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $5,525.00 | General |
| 12/10/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| 12/05/2024 | Genentech, Inc. | — | — | Cash or cash equivalent | $1,610.00 | Research |
| Study: UC P3: Double-Blind Treat Straight Through | ||||||
| 12/04/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $276.76 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/03/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/28/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,251.00 | General |
| 11/26/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $949.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/15/2024 | PFIZER INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $4,251.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $812.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,400.00 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,424.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/29/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 10/27/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 10/15/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 10/14/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $48.57 | General |
| Category: IMMUNOLOGY | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/25/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.99 | General |
| 09/21/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.99 | General |
| 09/21/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $47.08 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $54,670 | 41 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $42,410 | 42 |
| VELSIPITY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,350 | 5 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,920 | 3 |
| UC P3: Double-Blind Treat Straight Through | Genentech, Inc. | $4,428 | 3 |
| GED-0301-CD-001 | Celgene Corporation | $3,579 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED OPS-2071 FOR 12 WEEKS IN SUBJECTS WITH CROHNS DISEASE SHOWING SYMPTOMS OF ACTIVE INFLAMMATION DESPITE ONGOING TREATMENT | Otsuka Pharmaceutical Development & Commercialization, Inc. | $542.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 79 | 97 | $36,840 | $8,939 |
| 2022 | 4 | 106 | 125 | $52,960 | $13,070 |
| 2021 | 3 | 94 | 127 | $55,860 | $13,779 |
| 2020 | 3 | 96 | 119 | $43,680 | $8,346 |
Total Patients
375
Total Services
468
Medicare Billing
$44,132
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 40 | $12,400 | $2,878 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 25 | $11,000 | $2,873 | 26.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $8,640 | $1,996 | 23.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 16 | $4,800 | $1,191 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 26 | $11,440 | $3,460 | 30.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 22 | $11,880 | $2,866 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 24 | 28 | $8,680 | $2,441 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 14 | $8,120 | $1,839 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 18 | $7,740 | $1,296 | 16.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 17 | $5,100 | $1,168 | 22.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 24 | $10,560 | $3,267 | 30.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 25 | $13,500 | $3,176 | 23.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 32 | $13,760 | $2,790 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 32 | $9,920 | $2,617 | 26.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 14 | $8,120 | $1,930 | 23.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 23 | 23 | $12,420 | $2,844 | 22.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 18 | 35 | $15,050 | $2,590 | 17.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 25 | $7,750 | $1,564 | 20.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 14 | $4,060 | $675.62 | 16.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 19 | 22 | $4,400 | $672.32 | 15.3% |
About Dr. Bruce Sands, MD
Dr. Bruce Sands, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093706665.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Sands, MD has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $219,025 received in 2024. These payments were reported across 719 transactions from 43 companies. The most common payment nature is "Consulting Fee" ($673,814).
As a Medicare-enrolled provider, Sands has provided services to 375 Medicare beneficiaries, totaling 468 services with total Medicare billing of $44,132. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 11/02/2005
- Last Updated 06/10/2010
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093706665
Products in Payments
- XELJANZ (Drug) $195,615
- VELSIPITY (Drug) $65,864
- ENTYVIO (Biological) $51,621
- STELARA (Biological) $44,327
- Non-Covered Product (Drug) $28,072
- OMVOH (Drug) $22,000
- Humira (Biological) $18,269
- TREMFYA (Drug) $16,923
- Entyvio (Biological) $13,634
- CLENPIQ (Drug) $7,399
- ZEPOSIA (Drug) $7,140
- INFLECTRA (Biological) $6,525
- GED-0301 (Drug) $5,579
- XIFAXAN (Drug) $4,652
- ZYMFENTRA (Biological) $3,112
- SKYRIZI (Biological) $1,300
- Otezla (Drug) $1,250
- RINVOQ (Biological) $833.59
- HUMIRA (Biological) $550.00
- EPOGEN (Biological) $500.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554
Dr. Seth Gross, M.d, M.D
Gastroenterology — Payments: $746,602
Gastroenterology $746,602